Iterum Therapeutics plc (ITRM)
After hours:
| Previous Close | 0.2039 |
| Open | 0.2000 |
| Bid | 0.2050 x 1300 |
| Ask | 0.2069 x 1200 |
| Day's Range | 0.1976 - 0.2145 |
| 52 Week Range | 0.1750 - 2.5200 |
| Volume | |
| Avg. Volume | 1,122,485 |
| Market Cap | 36.427M |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7690 |
| Earnings Date | Mar 10, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 35,000 ordinary shares of the Company as an inducement to a newly hired employee. Th
- GlobeNewswire
Iterum Therapeutics Reports First Quarter 2022 Financial Results
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March
- GlobeNewswire
Iterum Therapeutics Provides Regulatory Update
DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it met with the US Food and Drug Administration (“FDA”) on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support t
